MX2009011250A - Promotor de la formacion de neuritas. - Google Patents

Promotor de la formacion de neuritas.

Info

Publication number
MX2009011250A
MX2009011250A MX2009011250A MX2009011250A MX2009011250A MX 2009011250 A MX2009011250 A MX 2009011250A MX 2009011250 A MX2009011250 A MX 2009011250A MX 2009011250 A MX2009011250 A MX 2009011250A MX 2009011250 A MX2009011250 A MX 2009011250A
Authority
MX
Mexico
Prior art keywords
promoter
neurite
formation
corneal
formation promoter
Prior art date
Application number
MX2009011250A
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Chiho Yabuta
Fumiko Yano
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Publication of MX2009011250A publication Critical patent/MX2009011250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee un agente para promover neuritogénesis de tejido ocular (promotor) y un uso farmacéutico del promotor; un agente para promover neuritogénesis de tejido ocular que contiene N-(1-acetilpiperidin-4-il)-4-fluorobenzamida o una sal farmacéuticamente aceptable de la misma, y un agente para promover neuritogénesis corneal y neuritogénesis retinal, que contiene N-(1-acetilpiperidin-4-il)-4-fluorobenzamida o una sal farmacéuticamente aceptable de la misma; el promotor de neuritogénesis corneal de la presente invención se usa para la mejora de sensibilidad de la córnea, tratamiento de resequedad de los ojos o un tratamiento de un trastorno epitelial de la córnea; el promotor de neuritogénesis retinal se usa para la mejora de una disfunción visual.
MX2009011250A 2007-04-20 2008-04-18 Promotor de la formacion de neuritas. MX2009011250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007112248 2007-04-20
PCT/JP2008/057583 WO2008133198A1 (ja) 2007-04-20 2008-04-18 神経突起形成促進剤

Publications (1)

Publication Number Publication Date
MX2009011250A true MX2009011250A (es) 2009-11-05

Family

ID=39925652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011250A MX2009011250A (es) 2007-04-20 2008-04-18 Promotor de la formacion de neuritas.

Country Status (11)

Country Link
US (1) US8637544B2 (es)
EP (1) EP2157082B1 (es)
JP (1) JP5179477B2 (es)
KR (1) KR101486605B1 (es)
CN (2) CN101687795B (es)
BR (1) BRPI0810093A2 (es)
CA (1) CA2684561C (es)
ES (1) ES2577539T3 (es)
MX (1) MX2009011250A (es)
RU (1) RU2442582C2 (es)
WO (1) WO2008133198A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10435444B2 (en) 2015-04-17 2019-10-08 The University Of Tokyo Agent for prevention or treatement of corneal disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
ITRM20010755A1 (it) * 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
US20060069104A1 (en) * 2002-04-10 2006-03-30 Toshio Matsuda Neurotrophic factor production accelerator
CN100413538C (zh) * 2002-10-31 2008-08-27 千寿制药株式会社 角膜疾病治疗剂
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제
JP4453642B2 (ja) 2005-10-19 2010-04-21 日産自動車株式会社 駆動系の制振制御装置
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents

Also Published As

Publication number Publication date
EP2157082A4 (en) 2011-03-30
CN103251592A (zh) 2013-08-21
EP2157082B1 (en) 2016-06-08
CN101687795B (zh) 2013-05-08
EP2157082A1 (en) 2010-02-24
CA2684561C (en) 2015-06-30
KR20090130142A (ko) 2009-12-17
RU2009142843A (ru) 2011-05-27
RU2442582C2 (ru) 2012-02-20
BRPI0810093A2 (pt) 2014-10-21
ES2577539T3 (es) 2016-07-15
KR101486605B1 (ko) 2015-01-26
JPWO2008133198A1 (ja) 2010-07-22
CA2684561A1 (en) 2008-11-06
CN101687795A (zh) 2010-03-31
JP5179477B2 (ja) 2013-04-10
CN103251592B (zh) 2015-07-29
WO2008133198A1 (ja) 2008-11-06
US20100144792A1 (en) 2010-06-10
US8637544B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
WO2009134371A3 (en) Composite lacrimal insert and related methods
AU2011338647A8 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
MY171920A (en) Prevention and treatment of ocular conditions
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
EA201270018A1 (ru) Опсинсвязывающие лиганды, композиции и способы использования
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
EP4360709A3 (en) Use of a vegf antagonist to treat angiogenic eye disorders
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
MY170198A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
IN2014CN03123A (es)
MY178169A (en) Topical ophthalmic peptide formulation
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
RU2017118405A (ru) Новое лечение роговицы с применением ламинина
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
MX2009011250A (es) Promotor de la formacion de neuritas.
WO2009089399A3 (en) Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
WO2012024419A3 (en) Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma

Legal Events

Date Code Title Description
FG Grant or registration